This study compared outcomes for 217 patients who received the MGuard stent versus 216 patients who received a bare metal stent for ST-elevation myocardial infarction. The MGuard stent aims to prevent distal embolization during angioplasty for STEMI. Results showed no differences in mortality, major adverse cardiac events, or cardiovascular mortality/non-fatal myocardial infarction between the groups. However, the rate of target lesion revascularization was significantly higher in the MGuard stent group compared to the bare metal stent group. The study concludes that the MGuard stent is a safe option for STEMI but is associated with a higher long-term rate of target lesion revascularization than bare metal stents.